<DOC>
	<DOCNO>NCT00009061</DOCNO>
	<brief_summary>The purpose study compare virus response GW433908/ritonavir ( RTV ) viral response nelfinavir ( NFV ) use abacavir ( ABC ) /lamivudine ( 3TC ) patient take antiretroviral ( ART ) drug .</brief_summary>
	<brief_title>Comparison GW433908/Ritonavir Nelfinavir When Used With Abacavir Lamivudine Patients That Have Not Taken Antiretroviral Drugs</brief_title>
	<detailed_description>Patients randomize 1 2 treatment arm . One arm treat GW433908/RTV plus ABC 3TC . The treated NFV plus ABC 3TC . Each group treat 48 week . The following compare 2 arm : 1 ) magnitude durability antiviral response ; 2 ) safety , tolerance , antiviral response 24 48 week therapy ; 3 ) time treatment failure ; 4 ) immunologic response ; 5 ) occurrence event related metabolic abnormality ; 6 ) development viral resistance subset patient follow treatment . Also study : 1 ) steady-state plasma drug trough concentration ; 2 ) demographic , virologic , immunologic , pharmacologic , adherence factor may associate treatment outcome ; 3 ) patient adherence drug regimens ; 4 ) study medication utilization ; 5 ) resource utilization .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are least 13 year old ( consent parent guardian need 18 ) . Agree use proven barrier method birth control ( e.g. , spermicide plus condom ) study period ( hormonal birth control accept ) , able child . Have receive less 4 week treatment nucleoside reverse transcriptase inhibitor ( NRTI ) never receive nonnucleoside reverse transcriptase inhibitor ( NNRTI ) protease inhibitor ( PI ) . Mothers previously receive 1 dose NNRTI nevirapine pregnancy prevention mothertochild HIV transmission permit enter study . Have viral load ( amount HIV blood ) 1,000 copies/ml . Exclusion Criteria Patients eligible study : Abuse drug alcohol way would interfere study requirement . Patients stable methadone consider study . Have active/acute CDC Category C event . Are unable absorb take medicine mouth . Are pregnant breastfeeding . Have serious medical condition ( diabetes , heart problem , hepatitis ) might affect safety patient . Have pancreatitis hepatitis within last 6 month . Have treat radiation chemotherapy within 28 day study drug take , need study . Have take drug affect immune system ( corticosteroid , interleukin , interferon ) antiHIV activity ( hydroxyurea foscarnet ) within 28 day study drug take . Have receive HIV vaccine within 3 month study drug take . Have receive certain drug within 28 day study drug take , think need study . Have receive experimental treatment . Have allergy might interfere study , opinion doctor .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2002</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>abacavir</keyword>
</DOC>